Roche is halting all studies for its Alzheimer’s drug gantenerumab after the anti-amyloid therapy failed two Phase III trials. The drug missed the primary endpoints of reducing cognitive decline and wasn’t as effective in removing beta-amyloid. (Endpoints News)
The Biden administration is renewing a request for additional COVID-19 and public health funding from Congress. The request would include $8.25 billion in COVID-19 aid, including the development of new vaccines and treatments for the evolving virus. (The Washington Post)
Google is piloting a project designed to incorporate its Care Studio search tool into electronic health records, with the goal of improving patient records. The hospitals involved in the pilot will measure the technology’s accuracy and efficacy in improving patient care. (STAT)
The Food and Drug Administration has raised concerns over Ardelyx’s kidney disease drug tenapanor due to uncertain benefits. The agency’s outside advisers plan to meet this week to discuss its most recent data on the drug. (Reuters)
Satsuma Pharmaceuticals’ experimental migraine treatment did not show statistical significance in results from a Phase III trial. Satsuma’s shares fell after the company released the results. (Yahoo Finance)
